within Pharmacolibrary.Drugs.ATC.J;

model J01RA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 20.0,
    adminDuration  = 600,
    adminMass      = 1.5,
    adminCount     = 1,
    Vd             = 0.018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Cefuroxime and metronidazole (ATC code J01RA03) is a fixed-dose combination of two antimicrobial agents. Cefuroxime is a second-generation cephalosporin antibiotic effective against a range of Gram-positive and Gram-negative bacteria, mainly used for perioperative prophylaxis and treatment of various infections. Metronidazole is an antiprotozoal and antibacterial agent particularly effective against anaerobic bacteria and protozoa, widely used for intra-abdominal and gynecological infections. This combination is used to provide broad-spectrum coverage for mixed infections, including surgical prophylaxis and treatment of intra-abdominal infections. Both drugs are approved and used in clinical practice.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic models were found for the fixed-dose cefuroxime and metronidazole combination. Instead, typical adult pharmacokinetic parameters for intravenous administration were estimated from literature for each component.</p><h4>References</h4><ol><li><p>Sullins, AK, &amp; Abdel-Rahman, SM (2013). Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. <i>Paediatric drugs</i> 15(2) 93–117. DOI:<a href=&quot;https://doi.org/10.1007/s40272-013-0017-5&quot;>10.1007/s40272-013-0017-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23529866/&quot;>https://pubmed.ncbi.nlm.nih.gov/23529866</a></p></li><li><p>Ongas, M, et al., &amp; Kipper, K (2017). Liquid chromatography-tandem mass spectrometry for the simultaneous quantitation of ceftriaxone, metronidazole and hydroxymetronidazole in plasma from seriously ill, severely malnourished children. <i>Wellcome open research</i> 2 43–None. DOI:<a href=&quot;https://doi.org/10.12688/wellcomeopenres.11728.2&quot;>10.12688/wellcomeopenres.11728.2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29479566/&quot;>https://pubmed.ncbi.nlm.nih.gov/29479566</a></p></li><li><p>Voesten, HG, et al., &amp; van der Meer, AL (1993). Optimizing antimicrobial prophylaxis in reconstructive vascular surgery. <i>VASA. Zeitschrift fur Gefasskrankheiten</i> 22(4) 342–346. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8310774/&quot;>https://pubmed.ncbi.nlm.nih.gov/8310774</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J01RA03;
